ERAS

As of 2026-09-10, ERAS scores 26out of 100 on QNTM’s five-factor quantitative model, a low conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. ERAS trades at $16.03, within its fair-value band.

ERAS scores 26 out of 100 on QNTM's five-factor model — a low-conviction reading — at 26 the factor profile is among the weaker names in the universe. Its strongest factor is volume at 41 (middling), where trading volume confirms genuine accumulation, followed by momentum at 40. The weakest is value at 0, where valuation looks stretched. Among Healthcare stocks it sits in the lower 4% of Healthcare names by composite.

On valuation, ERAS is priced around the middle of its recent range. The blended composite before the macro overlay was 27. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on ERAS, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where ERAS sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for ERAS runs $10.33–$21.45. Current price $16.03 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.